Eversense 365 cleared in the U.S. as an integrated continuous glucose monitoring (iCGM) system for people with diabetesWith a single sensor, the Eversense 365 system provides one year of use, versus 10-14 days with short-term CGM’s for minimal life disruptionLaunch expected early in the fourth quarter of| www.senseonics.com
Discover the findings of a recent study on implantable continuous glucose monitors (CGMs) and their potential to transform glucose monitoring for individuals with diabetes. This groundbreaking research explores the accuracy, longevity, and feasibility of implantable CGM systems, bringing hope for improved diabetes management.| Connected in Motion
Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced the U.S. Food and Drug Administration (FDA) approval for the Simplera Sync™ sensor for use with the...| Medtronic News